FDA Reauthorizes Juul's Menthol and Tobacco E-Cigarettes Amid Controversy
The FDA has allowed Juul to continue selling menthol and tobacco e-cigarettes, citing benefits for adult smokers despite previous health risk concerns.
Overview
The FDA has authorized Juul to sell menthol-flavored vapes, one of only two companies permitted to do so in the U.S.
Regulators believe the benefits of Juul's e-cigarettes for adult smokers outweigh the associated health risks, based on studies.
Juul, once valued at over $13 billion, has been pivotal in the vaping industry with its innovative e-cigarette designs.
Despite a previous order to remove its products from the market in June 2022, the FDA has reauthorized Juul's sales following controversies.
Juul faces scrutiny for its marketing practices, particularly regarding allegations of targeting young consumers, even as it continues to sell e-cigarettes.
Analysis
Center-leaning sources frame the FDA's decision on Juul by consistently emphasizing the company's controversial history and its widely perceived role in sparking the teen vaping trend. The narrative highlights past lawsuits, public opposition, and the negative societal impact of Juul's products, contextualizing the regulatory approval within a broader story of public health concerns and corporate accountability.
Sources (4)
FAQ
No FAQs available for this story.
History
This story does not have any previous versions.